Most cancer drugs approved by EMA show little benefit: study
The research, published in the BMJ, looked at the 48 cancer drugs in 68 indications approved by the Agency over the four-year time period. Of these, eight indications (12%) were approved on the basis of a single-arm study. At the time of market approval, 24 (35%) of the indications showed significant prolongation of survival and seven (10%) showed improved in quality of life.